Pregabalin: A new anxiolytic

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 663-672

  Lauria Horner, Bianca A ^a   Pohl, Robert B ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anticonvulsants; Anxiety disorders; Anxiolytic; GABA enhances; Pregabalin

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ALCOHOL; ALPRAZOLAM; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BICUCULLINE; BUSPIRONE; CALCIUM CHANNEL; CARBAMAZEPINE; CHLORDIAZEPOXIDE; DIURETIC AGENT; GABAPENTIN; INSULIN; LORAZEPAM; OPIATE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; OXYCODONE; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; PLACEBO; PREGABALIN; PROTEIN SUBUNIT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VINCRISTINE;

ANGIOSARCOMA; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ATAXIA; BEHAVIOR DISORDER; BINDING SITE; BLOOD BRAIN BARRIER; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CLINICAL TRIAL; CONFLICT; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; ETHOLOGY; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; HYPERALGESIA; MYOCLONUS; NAUSEA; NERVE CELL EXCITABILITY; NEUROMODULATION; NONHUMAN; PANIC; PERIPHERAL NERVOUS SYSTEM; REVIEW; SEXUAL DYSFUNCTION; SLEEP; SOCIAL PHOBIA; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; VERTIGO; VOLUNTEER; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS; GAMMA-AMINOBUTYRIC ACID; HUMANS;

EID: 0037399193     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.663     Document Type: Review

References (76)

1. KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19.
2. SCHNEIER FR, JOHNSON J, HORNIG CD, LIEBOWITZ MR, WEISSMAN MM: Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch. Gen. Psychiatry (1992) 49:282-288.
3. KESSLER RC, DUPONT RL, BERGLUND P, WITTCHEN HU: Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry (1999) 156:1915-1923.
4. KHAN A, LEVENTHAL RM, KHAN S, BROWN WA: Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J. Affect. Disord. (2002) 68:183-190.
5. GELENBERG A: Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment. Primary Care Companion J. Clin. Psychiatry (2000) 2:49-54.
6. BALLENGER J, DAVIDSON J, LECRUBIER Y, NUTT D: A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care. International Consensus Group on Depression and Anxiety. Prim. Care Companion J. Clin. Psychiatry (2001) 3:44-52.
7. ANDRUSZKIEWICZ RS, SILVERMAN RB: A convenient synthesis of 3-alkyl-4-aminobutanoic acids. Synthesis (1989):953-955.
8. TAYLOR CP, VARTANIAN MG: Profile of anticonvulsant activity of CI-1008 (Pregabalin) in animal model. Epilepsia (1997) 38(Suppl. 8):35.
9. CZUCZWAR SJ, PATSALOS PN: The new generation of GABA enhancers: Potential in the treatment of epilepsy. CNS Drugs (2001) 15(5):339-350.
10. BRYANS JS, WUSTROW DJ: 3-Substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. (1999) 19(2):149-177.
11. DIMOND KR, PANDE AC, LAMOREAUX L, PIERCE MW: Effect of gabapentin (neurotonin) on mood and well-being in patients with epilepsy. Prog. Neuro-Psychopharmacol. Biol. Psychiatry (1996) 20:407-417.
12. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology (2002) 42:229-236.
13. 2δ subunit of a calcium channel. J. Biol. Chem. (1996) 271(10):5768-5776.
14. WHITWORTH TL, QUICK MW: Upregulation of γ-aminobutyric acid transporter expression: role of alkylated γ-aminobutyric acid derivatives. Biochem. Soc. Trans. (2001) 29(6):736-741.
15. FIELD MJ, OLES RJ, LEWIS AS, MCCLEARY S, HUGHES J, SINGH I: Gabapentin (neuroptin) and S (+)-3-isolbutylgaba represent a novel class of selective antihyperalgesic agents. Br. J. Pharmacol. (1997) 121:1513-1522.
16. FIELD MJ, HOLLOMAN EF, MCCLEARY S, HUGHES J, SINGH L: Evaluation of gabapentin and S (+)-3-isobutylgaba in a rat model of postoperative pain. J. Pharmacol. Exp. Ther. (1997) 282:1242-1246.
17. FIELD MJ, MCCLEARY S, HUGHES J, SINGH L: Gabapentin and pregabalin, but not morphine and amitripyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain (1999) 80:391-398.
18. HOUGHTON AK, JU Y, WESTLUND KN: S (+)-3-isobutylgaba and its stereoisomer reduces the amount of inflammation and hyperalgesia in an acute animal model in the rat. J. Pharmacol. Exp. Ther. (1998) 285:533-538.
19. CORRIGAN BW, POOL WF, POSVAR EL et al.: Metabolic disposition of pregabalin in healthy volunteers. Clin. Pharmacol. Ther. (2001) 69(2):18 (Abstract PI-68).
20. BOCKBRADER HN, HUNT T, STRAND J et al.: Pregabalin pharmacokinetics and safety in healthy volunteers: results from two Phase I studies. Neurology (2000) 54(7, Suppl. 3) (Abstract 421).
21. BUSCH JA, STRAND JC, POSVAR EL et al.: Synopsis of two Phase I trials showing the main pharmacokinetics properties of pregabalin. Pregabalin (CI-1008) single-dose pharmacokinetics and safty/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia (1998) 39(Suppl. 6):58.
22. SELAK I: Pregabalin (Pfizer). Curr. Opin. Investig. Drugs (2001) 2(6):82-34.
23. STEWART BH, KUGLER AR, THOMPSON PR, BOCKBRADER HN: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. (1993) 10:276-281.
24. VOLLMER KO, ANHUT H, YHOMANN P, WAGNER F, JAHNCHEN D: Pharmacokinetic model and absolute bioavailability of the new anticonvulsant Gabapentin. Adv. Epileptol. (1989) 17:209-211.
25. PENUCCA E: Global evaluation of Phase III trial, efficacy and safety of pregabalin as add-on treatment in patients with partial seizures. New Anti-Epileptic Drugs - Fifth Eilat Conference, Eilat, Israel. IDdb Meeting Report (2000).
26. DEVINSKY O, CRAMER J: Safety and efficacy of new anti-epileptic drugs. J. Neurol. (2000) 55(11):11-16.
27. LACOBELLIS D, ALLEN R, LAMOUREAUX L, POOL RM: A double-blind, placebo controlled, trial of pregabalin for the treatment of painful diabetic neuropathy. Neurology (2000) 54(7, Suppl. 3):177 (Abstract).
28. BACKONJA M, BEYDOUN A, EDWARDS KR. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with epilepsy. J. Am. Med. Assoc. (1998) 280(21):1831-1836.
29. HILL CM, BALKENOHL M, THOMAS DW, WALKER R, MATHÉ H, MURRAY G: Pregabalin inpatients with postoperative dental pain. Eur. J. Pain (2001) 5:119-124.
30. ANDREWS N, LOOMIS S, BLAKE R, FERRIGAN L, SINGH L, MCKNIGHT AT: Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (2001) 157:381-387.
31. 3H] glutamate from rat caudal trigeminal nucleus slices. Pain (2001) 93:191-196.
32. FRENCH JA, MALICSI JR, KUGLER AR, KNAPP LE, BOCKBRADER HN, GARAFOLO EA: Pregabalin adjunct therapy in patients with partial seizures. Epilepsia (1999) 40(S7):106.
33. BEYDOUN A, UTHMAN BM, RAMSAY RE et al.: Pregabalin add-on trial: a double-blind, multi-centre study in patients with partial seizures. Epilepsia (1999) 40(S7):10.
34. CORBIN A, YOUNG J, LAMOREAUX L: MI Pregabalin reduces pain in patients with postherpetic neuralgioa: Supportive data from SF-Mcgill Pain Questionnaire (SF-MPQ). J. Pain (2002) 3(2, Suppl. 1):47 (Abstract).
35. PANDE AC, CROCKATT JC, JANNEY C et al.: Pregabalin treatment of generalized anxiety disorder (GAD) 2000: Three randomized placebo controlled trials. Eur. Psychiatry (2000) 15:244S.
36. FELTNER DE, POLLACK MH, DAVIDSON JRT et al.: A placebo-controlled, double-blind study of pregabalin treatment of social phobia: outcome and predictors of response. American Psychiatric Association (2002) (Abstract).
37. ROSNER H, RUBIN L, KESTENBAUM A: Gabapentin adjunctive therapy in neuropathic pain states. Clin. J. Pain (1996) 12:56-58.
38. ROWBOTHAM M, HARDEN N, STACEY B et al.: Gabapentin for the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA (1998) 280:1837-1842.
39. ROSENBERG JM, HARRELL C, RISTIC H, WERNER RA, DE ROSAYRO AM: The effect of gabapentin on neuropathic pain. Clin. J. Pain (1997) 13:251-255.
40. SIST TC, FILADORA VA II, MINER M, LERNA M: Experience with gabapentin for neuropathic pain in the head and neck: report of ten cases. Reg. Anesth. (1997) 22:473-478.
41. MELLICK GA, MELLICK LB: Reflex sympathetic dystrophy treated with gabapentin. Arch. Phys. Med. Rebabil. (1997) 78:98-105.
42. PANDE AC, DAVIDSON JR, JEFFERSON JW et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. (1999) 19:341-348.
43. ADELMAN JU, ADELMAN LC, VON SEGGERN R: Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache (2002) 42(10):978-983.
44. MATHEW NT: Antiepileptic drugs in migraine prevention. Headache (2001) 41(Suppl. 1):S18-S24.
45. SOLARO C, LUNARDI GL, CAPELLO E et al.: An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis. Neurology (1998) 51(2):609-611.
46. MUELLER ME, GRUENTHAL M, OLSON WL, OLSON WH: Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch. Phys. Med. Rehabil. (1997) 78:521-524.
47. HOUTCHENS MK, RICHERT JR, SAMI A, ROSE JW: Open label gabapentin treatment for pain in multiple sclerosis. Mult. Scler. (1997) 3:250-253.
48. AVERBUCH-HELLER L, TUSA RJ, FUHRY L et al.: A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann. Neurol. (1997) 41:818-825.
49. ADLER CH: Treatment of restless legs syndrome with gabapentin. Clin. Neuropharmacol. (1997) 20:148-151.
50. EVIDENTE VG, ADLER CH, CAVINESS JN, GWINN KA: Effective treatment of orthostatic tremor with gabapentin. Mov. Disord. (1998) 13(5):829-831.
51. MILLER RG, MOORE D, YOUNG LA et al.: Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology (1996) 47:1383-1388.
52. 3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur. J. Pharmacol. (Mol. Pharmacol. Section) (1993) 244:303-309.
53. TAYLOR CP, VARTANIAN MG, YUEN P-W, BIGGE C, SUMAN-CHAUHAN N, HILL DR: Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. (1993) 14:11-15.
54. SUMAN-CHAUHAN N, WEBDALE L, HILL DR, WOODRUFF GN: Characterization of [3H]-gabapentin binding to a novel site in the rat brain: homogenate binding studies. Eur. J. Pharmacol. (1993) 244:293-301.
55. 2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br. J. Pharmacol. (2000) 130:900-906.
56. +-induced synaptosomal calcium by gabapentin. Brain Res. (2000) 875:157-159.
57. DOOLEY DJ, MIESKE CA, BOROSKY SA: Inhibition of K (+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. (2000) 280:107-110.
58. DOOLEY DJ, DONOVAN CM, PUGSLEY TA: Stimulus-dependent modulation of [3H]-norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther. (2000) 295:1086-1093.
59. DOOLEY DJ, BARTOSZYK GD, HARTENSTEIN J et al.: Preclinical pharmacology of gabapentin. Golden Jubilee Conference and Northern European Epilepsia Meeting, University of York, York, UK (Abstract 8).
60. HELMER CA, DOOLEY DJ: Differential effects of gabapentin and pregabalin on stimulation - evoked catecholamine release from rat brain slices. DJ Soc. Neurosci. Abstr. (1998) 24(1):353.
61. PUGSLEY TA, WHETZEL SZ: Effects Of pregabatin (S-(+)-3-isobutylgaba, CI-1008 on the 3,4 diaminopyridine (DAP)-induced decrease in catecholamine synthesis in the rat brain. SZ Soc. Neurosci. Abstr. (1999) 25(2):744.11.
62. NG GY, BERTRAND S, SULLIVAN R et al.: Gamma-aminobutyric acid type B receptors with a specific heterodimer composition and post-synaptic actions in hippocampal neurons are targets of anticonvulsants gabapentin action. Mol. Pharmacol. (2001) 59:144-152.
63. NOZAKI-TAGUCHI N, CHAPLAN SR, HIGUERA ES, AJAKWE RC, YAKSH TL: Vincristine-induced allodynia in the rat. Pain (2001) 93(1):69-76.
64. CHEN S-R, XU Z, PAN H-L: Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology (2001) 95(6):1473-1479.
65. FIELD MJ, OLES RJ, SINGH L: Pregabalin may represent a novel class of anxiolytics agents with a broad spectrum of activity. Br. J. Pharmacol. (2001) 132:1-4.
66. PFIZER, INC.: Pfizer restricts use of pregabalin for some clinical trial patients. (12 February 2001) (Press release).
67. HINDMARCH I, DAWSON J, STANLEY N: The effects of pregabalin (CI-1008), alprazolam, and placebo on cognitive and psychomotor function, car driving, and aspects of sleep in healthy volunteers. American Psychiatric Association (2002) (Abstract).
68. HINDMARCH I, DAWSON J, STANLEY N: Evaluation of cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers. American Psychiatric Association (2002) (Abstract).
69. POLLACK MH, FELTNER DE, RICKELS K et al.: A placebo controlled, double blind study of pregabalin in treatment of generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
70. RICKELS K, POLLACK MH, LYDIARD RB et al.: Efficacy and safety of pregabalin and alprazolam in generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
71. POHL RB, ZIMBROFF DL, HARTFORD J et al.: Pregabalin: efficacy in generalized anxiety disorder using a BID regimen. American Psychiatric Association (2002) (Abstract).
72. FELTNER DE, POHL R, ZIMBROFF DL et al.: A placebo-controlled, double-blind study of pregabalin dosed twice daily in the treatment of generalized anxiety disorder. American Psychiatric Association (2002) (Abstract).
73. KASPER S, BLAGDEN M, SEGHERS S et al.: A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. American Psychiatric Association (2002) (Abstract).
74. KAVOUSSI R, CROCKATT J, WERTH JL, LIU-DUMAW M, PANDE AC: Pregabalin reduced depressive symptoms in patients with generalized anxiety disorder. American Psychiatry Association (2002) (Abstract).
75. FAKHOURY TA et al.: Long term safety and efficacy of pregabalin. Epilepsia (1999) 40(Suppl. 7):147 (Abstract).
76. HUPPERTZ H-J, FEUERSTEIN TJ, SCHULZE-BONHAGE A: Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia (2001) 42(6):790-792.